drugset / Trial / NCT02757885
Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to learn if it is possible and safe to treat persons with severe sickle cell disease (SCD) by bone marrow transplant (BMT) from human leukocyte antigen (HLA) half-matched related donors. Preparation before transplant includes the chemotherapy drugs hydroxyurea, fludarabine, thiotepa, anti-thymocyte globulin, and cyclophosphamide. It also includes radiation.
Timeline
- Start
- 2019-07-10
- Primary completion
- 2021-12-12
- Completion
- 2021-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cyclophosphamide | Other / unclassified | 50 mg/kg | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Background | Hydroxyurea | Other / unclassified | 30 mg/kg | Oral |
| Background | Thiotepa | Other / unclassified | 10 mg/kg | Intravenous |